Senores Pharmaceuticals Ltd IPO

Senores Pharmaceuticals Ltd IPO

Pharmaceuticals

mainboard

Bidding period

20 Dec 2024 - 24 Dec 2024

Bid price

₹391.00 - ₹391.00

Listing on

BSE, NSE

Listing date

30 Dec 2024

Lot size

38 shares

Issue size

₹582.11 crore


Minimum investment

₹14,858.00 / 1 lot

Maximum investment

₹1,93,154.00 / 13 lot

Bidding closed on 24 Dec 2024

EXPLORE IPOs
EXPLORE IPOs

Senores Pharmaceuticals Ltd IPO dates

IPO opening date

20 Dec 2024

IPO end date

24 Dec 2024

Allotment date

26 Dec 2024

Initiation of refunds

26 Dec 2024

Credit of shares to demat

27 Dec 2024

IPO listing date

30 Dec 2024

Senores Pharmaceuticals Ltd IPO financials

Particulars

For the period ending in March 2024 (in ₹ million)

Total assets ₹621.88
Total liabilities ₹621.88
Total expenditure ₹192.40
Total revenue ₹217.34
Profit after tax ₹31.45
EBITDA ₹44.41
Adjusted EBITDA ₹0.00

Senores Pharmaceuticals Ltd shareholder pattern

Pre-issue Post-issue
Promoter group 66.66 45.76
Public group 33.34 54.24

Senores Pharmaceuticals Ltd strengths and risks

Information currently unavailable

  • Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.

  • Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.

  • Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.

  • Presence in the Emerging Markets with a product portfolio, including specialty or complex products.

  • R&D capabilities driving our differentiated portfolio of products.

  • Professional management teams for our diverse business verticals.

  • The company business is dependent on the sale of its products through third party marketing partners and distributors. The loss of one or more marketing partners or distributors, the deterioration of their financial condition or prospects, or a reduction in their demand for its products or the company inability to maintain and increase the number of its arrangements for the marketing and distribution of the company products could adversely affect its business, results of operations, financial conditions and cash flows.

  • The company business is dependent on the sale of its products and continued growth of the Regulated Markets. Decrease in market growth for its product or failures to respond to change in market conditions could adversely affect its business, results of operations, financial conditions and cash flows.

  • Failures to comply with the quality standards and technical specifications prescribed by its customers may lead to loss of business from such customers and could negatively impact its business, results of operations and financial condition, including cancellation of existing and future orders which may expose it to warranty claims.

  • The company derives a part of its revenue from few customers. If one or more of such customers choose not to source their requirements from it or to terminate the company contracts or purchase orders, its business, cash flows, financial condition and results of operations may be adversely affected.

  • The company has had negative cash flows from operating activities in the last three Fiscal years and may continue to have negative cash flows in the future which could have an impact on its business and operations.

  • The pharmaceutical market is subject to regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose it to litigation or other liabilities, which could adversely affect its reputation, business, financial condition and results of operations. There have been instances in the past where the company drugs failed to meet standards prescribed under applicable law and action was taken against it by regulatory authorities.

  • The company derives a major portion of its revenue from its operations in the United States. A reduction in demand for the company products in these regions could adversely affect its business, results of operations, financial conditions and cash flows.

  • Any manufacturing or quality control problems may damage its reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, results of operations and financial condition.

  • Some of its Directors and Promoters may have interest in entities, which are in businesses similar to its and this may result in conflict of interest with it. Further, certain of its Promoter Group, Subsidiaries and Group Companies are in the same line of business as it, which may result in a conflict of interest.

  • The erstwhile statutory auditors of the Company have issued a qualified opinion in connection with their audit report for Fiscal 2022.

How to check the allotment status of the Senores Pharmaceuticals Ltd IPO?

To check the IPO allotment status, follow these steps:

 

  1. Visit the official website of the IPO’s registrar.
  2. Go to the IPO allotment status page.
  3. Select the ‘Senores Pharmaceuticals Ltd’ from the list of available IPOs.
  4. Enter your PAN, Demat ID, or application number.
  5. Click on ‘Submit’ or ‘Check Status’ to view your allotment details.

Alternatively, you can also check the allotment status on stock exchange websites such as the NSE or BSE.

To check the IPO allotment status, follow these steps:

 

  1. Visit the official website of the IPO’s registrar.
  2. Go to the IPO allotment status page.
  3. Select the ‘Senores Pharmaceuticals Ltd’ from the list of available IPOs.
  4. Enter your PAN, Demat ID, or application number.
  5. Click on ‘Submit’ or ‘Check Status’ to view your allotment details.

Alternatively, you can also check the allotment status on stock exchange websites such as the NSE or BSE.

Read more Read less

Senores Pharmaceuticals Ltd IPO registrar

MUFG Intime India Pvt Ltd

Phone number +91 8108114949
E-mail ID senorespharma.ipo@linkintime.co.in
Website www.linkintime.co.in

Senores Pharmaceuticals Ltd IPO reservation

QIB shares offered

44,43,817 (29.85%)

NII (HNI) shares offered

22,21,909 (14.92%)

Retail shares offered

14,81,272 (9.95%)

Anchor investor shares offered

66,65,726 (44.77%)

Total shares offered

1,48,87,724

Total shares with anchor investor

1,48,87,724

Senores Pharmaceuticals Ltd IPO lead manager

  • Equirus Capital Pvt Ltd
  • Ambit Pvt Ltd
  • Nuvama Wealth Management Ltd

Explore other IPOs

Aditya Infotech Limited logo
Aditya Infotech Limited logo

Aditya Infotech Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Advance Agrolife Limited logo
Advance Agrolife Limited logo

Advance Agrolife Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Advanced SysTek Limited logo
Advanced SysTek Limited logo

Advanced SysTek Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Aegis Vopak Terminals Limited logo
Aegis Vopak Terminals Limited logo

Aegis Vopak Terminals Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Agilus Diagnostics Limited logo
Agilus Diagnostics Limited logo

Agilus Diagnostics Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Airox Technologies Limited logo
Airox Technologies Limited logo

Airox Technologies Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Ajay Poly Limited logo
Ajay Poly Limited logo

Ajay Poly Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
All Time Plastics Limited logo
All Time Plastics Limited logo

All Time Plastics Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Allchem Lifescience Limited logo
Allchem Lifescience Limited logo

Allchem Lifescience Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Amanta Healthcare Limited logo
Amanta Healthcare Limited logo

Amanta Healthcare Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Anand Rathi Share AND Stock Brokers Limited logo
Anand Rathi Share AND Stock Brokers Limited logo

Anand Rathi Share AND Stock Brokers Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Anlon Healthcare Limited logo
Anlon Healthcare Limited logo

Anlon Healthcare Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Anthem Biosciences Limited logo
Anthem Biosciences Limited logo

Anthem Biosciences Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
AOne Steels India Limited logo
AOne Steels India Limited logo

AOne Steels India Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Ardee Engineering Limited logo
Ardee Engineering Limited logo

Ardee Engineering Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Armee Infotech Limited logo
Armee Infotech Limited logo

Armee Infotech Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Asirvad Microfinance Limited logo
Asirvad Microfinance Limited logo

Asirvad Microfinance Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Atlanta Electricals Limited logo
Atlanta Electricals Limited logo

Atlanta Electricals Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Avanse Financial Services Limited logo
Avanse Financial Services Limited logo

Avanse Financial Services Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced

How to apply for an IPO with Bajaj Broking?

adafafds
 
 
  • Log in to the Bajaj Broking trading platform and select ‘IPO’ from the menu.
  • Browse the list of open IPOs and click ‘Apply’ for your chosen IPO.
  • Enter the quantity and your UPI ID.
  • Submit your application—and you're done!

Frequently asked questions

What is the listing date for the Senores Pharmaceuticals Ltd IPO?

The listing date for the Senores Pharmaceuticals Ltd IPO is 30 Dec 2024.

What is the issue size of Senores Pharmaceuticals Ltd IPO?

The issue size of the Senores Pharmaceuticals Ltd IPO is ₹582.11 cr.

What is the minimum lot size needed for Senores Pharmaceuticals Ltd IPO?

The minimum lot size for Senores Pharmaceuticals Ltd IPO is 38

When does the Senores Pharmaceuticals Ltd open and close?

Senores Pharmaceuticals Ltd IPO is open from 20 Dec 2024 to 24 Dec 2024.

How can I apply for the Senores Pharmaceuticals Ltd IPO?

To apply for the Senores Pharmaceuticals Ltd, follow the steps given below:

  • Log in to your Bajaj Broking trading account and navigate to the current IPOs section.
  • Browse the list of open IPOs and click ‘Apply’ for your chosen PO.
  • Enter the quantity and your UPI ID. You will receive a mandate notification to block funds in your UPI app.
SHOW MORE SHOW LESS

Disclaimer

*Disclaimer for Bajaj Finance Limited (‘BFL’):

Stock trading business is carried by Bajaj Financial Securities Limited ("BFSL"), a broker and Depository Participant registered with Securities Exchange Board of India and offers various products/services related to Securities market (Securities market products/services). BFL merely facilitates display of data shared by BFSL on its webpage/mobile application. Such data received from BFSL, or any of its service providers is on “as is” basis. BFL does not make any representation or warranty, express or implied, regarding accuracy, completeness of such data displayed herein.

When you opt to avail the Securities market products/services of BFSL by clicking on the BFSL weblink/mobile app, you will be redirected to BFSL's web page/mobile app for initiation and completion of the transaction. You are supposed to exercise independent diligence by reading all the related documents carefully before deciding to invest in Securities market Products/services.

BFL is a Non-Banking Financial Company carrying the business of acceptance of deposits and providing lending solutions to Retail and Corporate customers. BFL does not offer nor advice on Securities market products/services and shall not be liable or responsible for any of your investment decision."

**Disclaimer: For Bajaj Financial Securities Limited

Investments in securities market are subject to market risk, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. All leveraged intraday positions will be squared off the same day. There is no restriction on withdrawal of unutilised margin amount. Trade Recommendations are research-calls provided under the SEBI Research Analyst guidelines.
Visit https://www.bajajbroking.in/disclaimer for complete disclaimer.

Securities market Products/services are made available only at the discretion of BFSL and subject to the individual contractual terms and conditions of the respective Securities market products/services. You shall be the sole owner of any decision to invest in any BFSL's Securities market products/services.

Securities market products/services may be withdrawn or amended at any time by BFSL without notice and your recourse in such case would be directly to reach out BFSL at connect@bajajfinserv.in or 1800 833 8888.

Powered by Bajaj Financial Securities Limited (Bajaj Broking)